<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231005059625N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-25</date_registration>
      <primary_sponsor>Birjand University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effectiveness of intramuscular injection of Ketorolac with PCA pump Containing Morphine and Apotel in Pain control of Patients after Cesarean Section</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of intramuscular injection of Ketorolac with PCA pump Containing Morphine and Apotel in Pain control of Patients after Cesarean Section</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73064</url>
      <study_type>observational</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to enter the study, the basic information of the patient is recorded in the relevant forms. The referring patients were divided into two groups A (recipients of intramuscular ketorolac) and group B (recipients of PCA pump containing morphine and Apotel) by a simple random block method and homogenization of quadruple blocks (BAAB, ABBA, BABA, ABAB, BBAA, AABB), Blinding description: In order to blind the mothers, they will be aware of the generalities of the research, which is the creation of analgesia by drugs, but they will not know about the method of prescribing drugs based on the groups under study. 15 minutes after entering the recovery room and before the intervention to create analgesia, the patient's pain is measured and recorded based on the visual pain score (VAS). Then, for the patients 6, 12 and 24 hours after the operation, the questionnaire is completed by one of the trained nurses who is not part of the research team and is not aware of the groups under study. (It should be noted that in the patient questionnaire, the type of prescription drug is mentioned as group A and group B, and the nurse entering the data is not aware of the type of prescription drug.).</study_design>
      <phase>2-3</phase>
      <hc_freetext>Painlessness after surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: Intervention Group: In the intervention group, an Optofuser analgesia pump from Darman Gostar Sepano in Iran was used. This pump had a capacity of 100 cc and operated at a speed of 4 cc per hour. A bolus dose of 0.5 cc could be administered with a 15-minute lockout period. The medication administered through this pump consisted of 0.5 mg per kilogram of morphine combined with 40 mg per kilogram of Apotel, and it was diluted with normal saline to reach a total volume of 100 cc. Intervention 2: Intervention group2: Intervention group: Ketorolac, 30 mg in people under 50 kg and 60 mg in people over 50 kg as a deep intramuscular injection that is repeated every 8 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Protocol for the treatment of pain after cesarean section

When:
After the publication of the article

To whom:
Researchers of all disciplines

Conditions:
After the publication of the article

Where to obtain:
m.faghihshojaei@gmail.com

How to obtain:
m.faghihshojaei@gmail.com

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mersede Faghihshojaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghaffari blv - Birjand university of  medical science</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۷۱۷۸۵۳۰۷۶</zip>
        <telephone>+98 56 3238 5000</telephone>
        <email>m.faghihshojaei@gmail.com</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mersede Faghihshojaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghaffari blv - Birjand university of  medical science</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9717853076</zip>
        <telephone>+98 56 3238 5000</telephone>
        <email>m.faghihshojaei@gmail.com</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant mothers, 20-40 years old,
Elective caesarean section with transverse incision
Pregnancy age at least 37 weeks
American Society of Anesthesiology based on II and I ASA class</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Suffering from gestational hypertension
Receiving NSAID and narcotics before surgery
Mothers of macrosomic and multiple babies
Spinal or epidural anesthesia method
history of peptic ulcer
history of coagulation disorders
BMI more than 30</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: Intervention Group: In the intervention group, an Optofuser analgesia pump from Darman Gostar Sepano in Iran was used. This pump had a capacity of 100 cc and operated at a speed of 4 cc per hour. A bolus dose of 0.5 cc could be administered with a 15-minute lockout period. The medication administered through this pump consisted of 0.5 mg per kilogram of morphine combined with 40 mg per kilogram of Apotel, and it was diluted with normal saline to reach a total volume of 100 cc.</i_keyword>
      <i_keyword>Intervention group2: Intervention group: Ketorolac, 30 mg in people under 50 kg and 60 mg in people over 50 kg as a deep intramuscular injection that is repeated every 8 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determination and comparison of the average pain intensity of the patients after the cesarean section in the group receiving intramuscular ketorolac and the group receiving morphine and Apotel by PCA pump. Timepoint: , 15 minutes after the operation (before intervention for analgesia) and 6, 12 and 24 hours after the cesarean section. Method of measurement: Visual pain score(Visual Analogue Scale).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The mean of hemodynamic indices (average blood pressure, heart rate and SPO2). Timepoint: 15 minutes after the operation (before intervention for analgesia) and 6, 12 and 24 hours after the operation. Method of measurement: Automatic monitoring device.</sec_outcome>
      <sec_outcome>Frequency distribution of mothers' need to receive an additional dose of anesthesia. Timepoint: In the first 24 hours after the operation. Method of measurement: Based on the history of the patient.</sec_outcome>
      <sec_outcome>Frequency distribution of side effects (nausea, vomiting, abnormal sleepiness, respiratory depression, stomach pain). Timepoint: In the first 24 hours after the operation. Method of measurement: Based on the history of the patient.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Birjand University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-25</approval_date>
        <contact_name>Research Ethics Committees of Birjand University of Medical Sciences</contact_name>
        <contact_address>Ghaffari Blvd, Birjand University of Medical Sciences Birjand South Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
